He then echoed his earlier warnings and those of his colleague Professor Chris Whitty that the COVID-19 fight will be a long one, and it will be with us for good. So, from this should we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there were a single treatment that:
could stop the infection in its tracks, was anti-inflammatory; controlling the immune system’s response to the infection and stopping it from overreacting dangerously, in cases where patients developed secondary bacterial infections in the lungs could supercharge antibiotics; boosting their efficacy and eve, was a repurposed drug; already proven as safe was easy to make, scalable at the level required to make a difference in the pandemic and was cost-effective, then wouldn’t that be something we should all be getting excited about?
Surely though no such ‘silver bullet’ game-changing therapy exists? After all, the only treatments we hear about for COVID are those, which were either very new, expensive and experimental or have a very narrow application to a particular aspect of the disease.
Well, you heard it here first – such a ‘silver bullet’ treatment does exist today. It’s called Nylexa, from the small biotech company NovaBiotics Ltd. Its active ingredients have been safely used in medicines that treat unrelated conditions for over 30 years.
NovaBiotics discovered Nylexa’s potential benefits in COVID-19 following a decade of research in difficult to treat, drug-resistant infections, including the complex chest infections and inflammation associated with cystic fibrosis (CF) lung disease. In March they applied for a £1m grant from Innovate (representing the government) to start clinical studies. That grant was eventually awarded earlier this month, and the government is now considering whether or not to include Nylexa on two separate NHS platform studies.
But why I hear you ask if this is so good have we not heard about it before? Why are the government and the press not shouting about this from the rooftops? Why is this not being demanded by clinicians desperate for effective treatments for their patients?
I’m afraid to say, it all boils down to money. Small biotech companies find it difficult to get attention as they don’t have the resources available to their larger better-funded rivals. The names we read about regularly when it comes to groundbreaking new treatments are invariably large multi-national pharmaceutical companies with deep pockets and big budgets to promote their own particular wares. They make sure their drugs get the required attention. Nova Biotics is a small private company funded by a group of loyal and supportive shareholders so unfortunately don’t have the resources to compete for attention with the big boys. For more about corona sneltest stop by the webpage.
This is why this situation is so frustrating. In mitigating the health consequences of contracting COVID-19, Nylexa could increase public confidence in living with the virus for the longer term and potentially allow a greater degree of normality to return to the way in which we live, benefiting the economy directly in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. Yet getting people in positions of influence to take notice amongst all the others competing for their attention is very difficult indeed.
It is reported that there are thousands of potential COVID-19 treatments in clinical trials across the world. I would challenge anyone to show me one which has the same potential for positive impact as Nylexa, yet this is not currently part of any trial, despite its impeccable credentials. So come on Government, and ministers, get your finger out and get this drug into trials immediately. The sooner it gets tested, the sooner it can be used to help sort out the mess the pandemic has caused to all our lives.